Fate Of FOB Legislation Under New Congress Is Front And Center At BIO CEO Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO may be back to the drawing board in its lobbying push for lengthy exclusivity periods in follow-on biologics legislation, policy experts say.
You may also be interested in...
FOBs Help Wanted: Waxman Appeals To Obama
FDA should start approving follow-on biologics even in the absence of legislation, House committee chairman tells president in bid to increase his negotiating leverage.
FOBs Help Wanted: Waxman Appeals To Obama
FDA should start approving follow-on biologics even in the absence of legislation, House committee chairman tells president in bid to increase his negotiating leverage.
Genentech Projects Limited Impact From FOBs; Roche Says Outlook Less Rosy
Disclosures in tender offer documents could feed into legislative debate on biosimilars.